REFERENCES

1. .N. I. Girgis, Y. Sultan, Z. Farid et al., “Tuberculous meningitis, Abbassia Fever Hospital-U.S. Naval Medical Research Unit No. 3-Cairo, Egypt, from 1976 to 1996,” American Journal of Tropical Medicine and Hygiene, vol. 58, no. 1, pp. 28-34, 1998.
2. R. B. Rock, S. Hu, G. Gekker et al., “Mycobacterium tubercu-losis-induced cytokine and chemokine expression by humanmicroglia and astrocytes: effects of dexamethasone,” Journal of Infectious Diseases, vol. 192, no. 12, pp. 2054-2058, 2005.
3. R. Verdon, S. Chevret, J. P. Laissy, and M. Wolff, “Tuberculous meningitis in adults: review of 48 cases,” Clinical Infectious Diseases, vol. 22, no. 6, pp. 982-988, 1996.
4. S. J. Kent, S. M. Crowe, A. Yung, C. R. Lucas, and A. M. Mijch, “Tuberculous meningitis: a 30-year review,” Clinical Infectious Diseases, vol. 17, no. 6, pp. 987-994, 1993.
5. C. Bidstrup, P. H. Andersen, P. Skinhøj, and A^˚. B. Andersen, “Tuberculous meningitis in a country with a low incidence of tuberculosis: still a serious disease and a diagnostic challenge,” Scandinavian Journal of Infectious Diseases, vol. 34, no. 11, pp.811–814, 2002.
6. C. Vinnard, C. A. Winston, E. P. Wileyto, R. R. Macgregor, and G. P. Bisson, “Isoniazid-resistant tuberculous meningitis, United States, 1993–2005,” Emerging Infectious Diseases, vol. 17, no. 3, pp. 539–542, 2011.
7. M. C. Thigpen, C. G. Whitney, N. E. Messonnier et al., “Bac-terial meningitis in the United States, 1998–2007,” The New England Journal of Medicine, vol. 364, no. 21, pp. 2016–2025,2011.
8. A. R. Rich and H. A. McCordock, “The pathogenesis of tuber-culous meningitis,” Bulletin of the Johns Hopkins Hospital, vol. 52, pp. 5–37, 1933.
9. J. Berenguer, S. Moreno, F. Laguna et al., “Tuberculous menin-gitis in patients infected with the human immunodeficiency virus,” The New England Journal of Medicine, vol. 326, no. 10, 668–672, 1992.
10. L. S. Farer, A. M. Lowell, and M. P. Meador, “Extrapulmonary tuberculosis in the United States,” American Journal of Epi-demiology, vol. 109, no. 2, pp. 205–217, 1979.
11. J. Keane, S. Gershon, R. P. Wise et al., “Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent,” The New England Journal of Medicine, vol. 345, no. 15, pp.1098–1104, 2001.
12. Green PH. Tubercular meningitis. Lancet 1836; 26: 232–5.
13. Koch R. Die aetiologie der tuberculosis. Berlin Klinische Wochenshrift 1882; 19:232–5.
14. Rich AR, Mc Cordock HA. The pathogenesis of tubercu lous meningitis. Bull John Hopkins Hosp 1933; 52:5–37.
15. Dastur DK, Manghani DK, Udani PM. Pathology and pathogenetic mechanisms in neurotuberculosis. Radiol Clin North Am 1995; 33:733–52.
16. Thwaites GE, Macmullen-Price J, Tran TH, et al. Serial MRI to determine the effect of dexamethasone on the cerebral pathology of tuberculous meningitis: an obser-vational study. Lancet Neurol 2007; 6:230–6.
17. Laguna F, Adrados M, Ortega A, et al. Tuberculous meningitis with acellular cerebrospinal fluid in AIDS patients. AIDS 1992; 6:1165–7.
18. Karstaedt AS, Valtchanova S, Barriere R, et al. Tuber- culous meningitis in South African urban adults. QJM 1998; 91:743–7.
19. Jeren T, Beus I. Characteristics of cerebrospinal fluid in tuberculous meningitis. Acta Cytol 1982; 26:678–80.
20. Thwaites GE, Simmons CP, Than Ha Quyen N, et al. Pathophysiology and prognosis in vietnamese adults  with tuberculous meningitis. J Infect Dis 2003; 188:1105–15.
21. Thwaites GE, Chau TT, Farrar JJ. Improving the bac- teriological diagnosis of tuberculous meningitis. J Clin Microbiol 2004; 42:378–9.
22. Dieli F, Sireci G, Di Sano C, et al. Predominance of Vgamma9/Vdelta2T lymphocytes in the cerebrospinal fluid of children with tuberculous meningitis: reversal after chemotherapy. Mol Med 1999; 5:301–12.
23. Algood HM, Lin PL, Flynn JL. Tumor necrosis factor and chemokine interactions in the formation and main- tenance of granulomas in tuberculosis. Clin Infect Dis 2005;41(Suppl. 3):S189–93.
24. Sharief MK, Ciardi M, Thompson EJ. Blood-brain barrier damage in patients with bacterial meningitis: association with tumor necrosis factor-alpha but not interleukin-1 beta. J Infect Dis 1992; 166:350–8.
25. Tsenova L, Bergtold A, Freedman VH, et al. Tumor necrosis factor alpha is a determinant of pathogenesis and disease progression in mycobacterial infection in the central nervous system. Proc Natl Acad Sci USA 1999; 96:5657–62.
26. Tsenova L, Sokol K, Freedman VH, et al. A combin- ation of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death. J Infect Dis 1998; 177:1563–72.
27. Schoeman JF, Springer P, Ravenscroft A, et al. Adjunct-ive thalidomide therapy of childhood tuberculous men- ingitis: possible anti-inflammatory role. J Child Neurol
28. Schoeman JF, Springer P, van Rensburg AJ, et al. Adjun-ctive thalidomide therapy for childhood tuberculous meningitis: results of a randomized study. J Child Neurol 2004; 19:250–7.
29. Simmons CP, Thwaites GE, Quyen NT, et al. Pretreat-ment intracerebral and peripheral blood immune responses in Vietnamese adults with tuberculous men-ingitis: diagnostic value and relationship to disease severity and outcome. J Immunol 2006; 176:2007–14.
30. Simmons CP, Thwaites GE, Quyen NT, et al. The clin-ical benefit of adjunctive dexamethasone in tuberculous meningitis is not associated with measurable attenuation of peripheral or local immune responses. J Immunol 2005; 175:579–90.
31. Tobin DM, Vary JC Jr, Ray JP, et al. The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 2010; 140:717–30.
32. Tobin DM, Roca FJ, Oh SF, et al. Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 2012; 148:434–46.
33. N. J. Farinha, K. A. Razali, H. Holzel, G. Morgan, and V. M. Novelli, “Tuberculosis of the central nervous system in chil-dren: a 20-year survey,” Journal of Infection, vol. 41, no. 1, pp. 61–68, 2000.
34. A. H. Alzeer and J. M. FitzGerald, “Corticosteroids and tuber-culosis: risks and use as adjunct therapy,” Tubercle and Lung Disease, vol. 74, no. 1, pp. 6–11, 1993.
35. M. Henry and R. S. Hlzman, “Tuberculosis of the brain, meninges, and spinal cord,” in Tuberculosis, W. N. Rom, S. M. Garay et al., Eds., pp. 445–464, Lippincott Williams and Wilkins, Philadelphia, Pa, USA, 2nd edition, 2004.
36. R. Kumar, S. N. Singh, and N. Kohli, “A diagnostic rule for tuberculous meningitis,” Archives of Disease in Childhood, vol. 81, no. 3, pp. 221–224, and 1999.
37. G. E. Thwaites, T. T. H. Chau, K. Stepniewska et al., “Diagnosis of adult tuberculous meningitis by use of clinical and labora-tory features,” The Lancet, vol. 360, no. 9342, pp.1287–1292, 2002.
38. M. D. Iseman, A Clinician’s Guide to Tuberculosis, Lippincott Williams and Wilkins, Baltimore, Md, USA, 1999.  D. H. Kennedy and R. J. Fallon, “Tuberculous meningitis,”Journal of the American Medical Association, vol. 241, no. 3,264–268, 1979.
39. C. Vinnard, C. A. Winston, E. P. Wileyto, R. R. Macgregor, and G. P. Bisson, “Isoniazid resistance and death in patients with tuberculous meningitis: retrospective cohort study,” British Medical Journal, vol. 341, p. c4451, 2010.
40. E. D. Chan, L. Heifets, and M. D. Iseman, “Immunologic diag-nosis of tuberculosis: a review,” Tubercle and Lung Disease, vol. 80, no. 3, pp. 131–140, 2000.
41. B. K. Gupta, A. Bharat, B. Debapriya, and H. Baruah, “Ad-enosine deaminase levels in CSF of tuberculous meningitis patients,” Journal of Clinical Medicine Research, vol. 2, no. 5, Pp220–224, 2010.
42. I. Corral, C. Quereda, E. Navas et al., “Adenosine deaminase activity in cerebrospinal fluid of HIV-infected patients: limited value for diagnosis of tuberculous meningitis,” European Jour-nal of Clinical Microbiology and Infectious Diseases, vol. 23, no.6, pp. 471–476, 2004.
43. G. E. Thwaites, M. Caws, T. T. H. Chau et al., “Comparison of conventional bacteriology with nucleic acid amplification (amplified mycobacterium direct test) for diagnosis of tuber-culous meningitis before and after inception of antituberculo-sis chemotherapy,” Journal of Clinical Microbiology, vol. 42, no. 3, pp. 996–1002, 2004.
44. M. Pai, L. L. Flores, N. Pai, A. Hubbard, L. W. Riley, and J. M. Colford, “Diagnostic accuracy of nucleic acid amplification tests for tuberculous meningitis: a systematic review and meta-analysis,” The Lancet Infectious Diseases, vol. 3, no. 10, pp. 633– 643, 2003.
45. V. Jonas, M. J. Alden, J. I. Curry et al., “Detection and iden-tification of Mycobacterium tuberculosis directly from spu-tum sediments by amplification of rRNA,” Journal of Clini-cal Microbiology, vol. 31, no. 9, pp. 2410–2416, 1993.
46. S. Kusum, S. Aman, R. Pallab et al., “Multiplex PCR for rapid diagnosis of tuberculous meningitis,” Journal of Neurology, vol. 258, no. 10, pp. 1781–1787, 2011.
47. J. Dinnes, J. Deeks, H. Kunst et al., “A systematic review of ra-pid diagnostic tests for the detection of tuberculosis infection,” Health Technology Assessment, vol. 11, no. 3, pp. 1–196, 2007.
48. P. R. Donald, T. C. Victor, A. M. Jordaan, J. F. Schoeman, and P. D. van Helden, “Polymerase chain reaction in the diagnosis of tuberculous meningitis,” Scandinavian Journal of Infectious Diseases, vol. 25, no. 5, pp. 613–617, 1993.
49. M. Pienaar, S. Andronikou, and R. van Toorn, “MRI to dem-onstrate diagnostic features and complications of TBM not seen with CT,” Child’s Nervous System, vol. 25, no. 8, pp. 941– 947, 2009.
50. G. Thwaites, M. Fisher, C. Hemingway, G. Scott, T. Solomon, and J. Innes, “British Infection Society guidelines for the diag-nosis and treatment of tuberculosis of the central nervous sys-tem in adults and children,” Journal of Infection, vol. 59, no. 3, pp. 167–187, 2009.
51. M. Humphries, “The management of tuberculous meningitis,” Thorax, vol. 47, no. 8, pp. 577–581, 1992.
52. American Thoracic Society, Centers for Disease Control, and Infectious Diseases Society of America, “Treatment of tuber-culosis,” Morbidity and Mortality Weekly Report, vol. 52, no. RR-11, pp. 1–77, 2003.
53. L. M. Mofenson, M. T. Brady, S. P. Danner et al., “Guidelines for the prevention and treatment of opportunistic infections among HIV-Exposed and HIV-Infected children: recommen-dations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics,” Morbidity and Mortality Weekly Report. Recommendations and Reports, vol. 58, no. RR-11, pp. 1–166, 2009.
54. World Health Organization, Treatment of Tuberculosis: Guide-lines, 4th edition, 2010.
55. J. P. DeVincenzo, S. E. Berning, C. A. Peloquin, and R. N. Husson, “Multidrug-resistant tuberculous meningitis: clinical problems and concentrations of second-line antituberculous medications,” Annals of Pharmacotherapy, vol. 33, no. 11, pp. 1184–1188, 1999.
56. J. W. C. Alffenaar, R. van Altena, H. J. Bokkerink¨ et al., “Phar-macokinetics of moxifloxacin in cerebrospinal fluid and plas-ma in patients with tuberculous meningitis,” Clinical Infectious Diseases, vol. 49, no. 7, pp. 1080–1082, 2009.
57. J. J. Kelly, E. A. Horowitz, C. J. Destache, A. H. Fruin, and V. A. Long, “Diagnosis and treatment of complicated tubercular meningitis,” Pharmacotherapy, vol. 19, no. 10, pp. 1167–1172, 1999.
58. G. E. Thwaites, S. M. Bhavnani, T. T. H. Chau et al., “Random-ized pharmacokinetic and pharmacodynamic comparison of fluoroquinolones for tuberculous meningitis,” Antimicrobial Agents and Chemotherapy, vol. 55, no. 7, pp. 3244–3253, 2011.
59. A. Zuger, “Tuberculosis,” in Infections of the Central Nervous System, W. M. Scheld, R. J. Whitley, and C. M. Marra, Eds.,pp. 441–460, Lippincott Williams and Wilkins, Philadelphia, Pa, USA, 3rd edition, 2004.
60. G. E. Thwaites, N. T. N. Lan, N. H. Dung et al., “Effect of antituberculosis drug resistance on response to treatment and outcome in adults with tuberculous meningitis,” Journal of Infectious Diseases, vol. 192, no. 1, pp. 79–88, 2005.
61. E. D. Chan, D. Chatterjee, M. D. Iseman, and L. B. Heifets, “Pyrazinamide, ethambutol, ethionamide, and aminoglyco-sides,” in Tuberculosis, W. N. Rom and S. M. Garay, Eds., pp. 773–789, Lippincott Williams and Wilkins, Philadelphia, Pa, USA, 2004.
62. D. Heemskerk, J. Day, T. T. H. Chau et al., “Intensified treat-ment with high dose Rifampicin and Levofloxacin compared to standard treatment for adult patients with tuberculous meningitis (TBM-IT): protocol for a randomized controlled trial,” Trials, vol. 12, p. 25, 2011.
63. J. L. Gaillard, C. Silly, A. le Masne et al., “Cerebrospinal fluid penetration of Amikacin in children with community-ac-quired bacterial meningitis,” Antimicrobial Agents and Chem-otherapy, vol. 39, no. 1, pp. 253–255, 1995.
64. P. R. Donald, “Cerebrospinal fluid concentrations of antitu-berculosis agents in adults and children,” Tuberculosis, vol. 90, no. 5, pp. 279–292, 2010.
65. A. H. Diacon, A. Pym, M. Grobusch et al., “The diarylquino-line TMC207 for multidrug-resistant tuberculosis,” The New England Journal of Medicine, vol. 360, no. 23, pp. 2397–2405,2009.
66. S. Kaojarern, K. Supmonchai, P. Phuapradit, C. Mokkhavesa, and S. Krittiyanunt, “Effect of steroids on cerebrospinal fluid penetration of antituberculous drugs in tuberculous meningi-tis,” Clinical Pharmacology and Therapeutics, vol. 49, no. 1, pp. 6–12, 1991.
67. L. Hong, W. Jiang, H. Pan, Y. Jiang, S. Zeng, and W. Zheng, “Brain regional pharmacokinetics of p-aminosalicylic acid and its N-acetylated metabolite: effectiveness in chelating brain manganese,” Drug Metabolism and Disposition, vol. 39, no. 10, pp. 1904–1909, 2011.
68. R. Nau, F. Sorgel,¨ and H. Eiffert, “Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treat-ment of central nervous system infections,” Clinical Microbi-ology Reviews, vol. 23, no. 4, pp. 858–883, 2010.
69. L. J. Strausbaugh, C. D. Mandaleris, and M. A. Sande, “Com-parison of four aminoglycoside antibiotics in the therapy of experimental E. coli meningitis,” Journal of Laboratory and Clinical Medicine, vol. 89, no. 4, pp. 692–701, 1977.
70. A. M. Ginsberg, “Drugs in development for tuberculosis,” Drugs, vol. 70, no. 17, pp. 2201–2214, 2010.
71. E. C. Rivers and R. L. Mancera, “New anti-tuberculosis drugs with novel mechanisms of action,” Current Medicinal Chem-istry, vol. 15, no. 19, pp. 1956–1967, 2008.
72. C. C. Leung, T. H. Lam, W. M. Chan et al., “Diabetic control and risk of tuberculosis: a cohort study,” American              Journal of Epidemiology, vol. 167, no. 12, pp. 1486–1494, 2008.
73. J. de Gans and D. van Beek, “Dexamethasone in adults with bacterial meningitis,” The New England Journal of Medicine, vol. 347, no. 20, pp. 1549–1556, 2002.
74. T. H. Nguyen, T. H. Tran, G. Thwaites et al., “Dexamethasone in Vietnamese adolescents and adults with bacterial meningi-tis,” The New England Journal of Medicine, vol. 357, no. 24, pp. 2431–2440, 2007.
75. M. C. Brouwer, P. McIntyre, J. de Gans, K. Prasad, and D. van de Beek, “Corticosteroids for acute bacterial meningitis,” Co-chrane Database of Systematic Reviews, vol. 9, Article IDCD004405, 2010.
76. H. Spapen, G. van Berlaer, M. Moens, and I. Hubloue, “Ad-junctive steroid treatment in acute bacterial meningitis. “To do or not to do: that is the question”,” Acta Clinica Belgica, vol. 66, no. 1, pp. 42–45, 2011.
77. K. Prasad and M. B. Singh, “Corticosteroids for managing tuberculous meningitis,” Cochrane Database of Systematic Re-views, no. 1, p. CD002244, 2008.
78. G. E. Thwaites, D. B. Nguyen, H. D. Nguyen et al., “Dex-amethasone for the treatment of tuberculous meningitis in adolescents and adults,” The New England Journal of Medicine, vol. 351, no. 17, pp. 1741–1751, 2004.
79. N. I. Girgis, Z. Farid, M. E. Kilpatrick, Y. Sultan, and I. A. Mikhail, “Dexamethasone adjunctive treatment for tubercu-lous meningitis,” Pediatric Infectious Disease Journal, vol. 10, no. 3, pp. 179–183, 1991.
80. M. Curto, C. Reali, G. Palmieri et al., “Inhibition of cytokines expression in human microglia infected by virulent and non-virulent mycobacteria,” Neurochemistry International, vol. 44, no. 6, pp. 381–392, 2004.
81. C. M. Mastroianni, F. Paoletti, M. Lichtner, C. D’Agostino, V. Vullo, and S. Delia, “Cerebrospinal fluid cytokines in pa-tients with tuberculous meningitis,” Clinical Immunology and Immunopathology, vol. 84, no. 2, pp. 171–176, 1997.
82. L. Tsenova, K. Sokol, V. H. Freedman, and G. Kaplan, “A com-bination of thalidomide plus antibiotics protects rabbits from mycobacterial meningitis-associated death,” Journal of Infec-tious Diseases, vol. 177, no. 6, pp. 1563–1572, 1998.
83. L. Tsenova, A. Bergtold, V. H. Freedman, R. A. Young, and G. Kaplan, “Tumor necrosis factor α is a determinant of patho-genesis and disease progression in mycobacterial infection in the central nervous system,” Proceedings of the National Acad-emy of Sciences of the United States of America, vol. 96, no. 10,pp. 5657–5662, 1999.
84. K. Møller, F. S. Larsen, P. Bie, and P. Skinhøj, “The syndrome of inappropriate secretion of antidiuretic hormone and fluid restriction in meningitis—how strong is the evidence?” Scan-dinavian Journal of Infectious Diseases, vol. 33, no. 1, pp. 13–26,2001.
85. M. Gelabert and M. Castro-Gago, “Hydrocephalus and tuber-culous meningitis in children. Report on 26 cases,” Child’s Nervous System, vol. 4, no. 5, pp. 268–270, 1988.
86. W. C. Clark, J. C. Metcalf Jr., M. S. Muhlbauer, F. C. Dohan Jr., and J. H. Robertson, “Mycobacterium tuberculosis meningitis: a report of twelve cases and a literature review,” Neurosurgery, vol. 18, no. 5, pp. 604–610, 1986.
87. A. P. Chugh, M. Husain, R. K. Gupta, B. K. Ojha, A. Chandra, and M. Rastogi, “Surgical outcome of tuberculous meningitis hydrocephalus treated by endoscopic third ventriculostomy: prognostic factors and postoperative neuroimaging for func-tional assessment of ventriculostomy,” Journal of Neurosurgery: Pediatrics, vol. 3, no. 5, pp. 371–377, 2009.
88. S. Kemaloglu, U. Ozkan, Y. Bukte, A. Ceviz, and M. Ozates, “Timing of shunt surgery in childhood tuberculous meningitis with hydrocephalus,” Pediatric Neurosurgery, vol. 37, no. 4, pp. 194–198, 2002.
89. D. Lamprecht, J. Schoeman, P. Donald, and H. Hartzenberg, “Ventriculoperitoneal shunting in childhood tuberculous meningitis,” British Journal of Neurosurgery, vol. 15, no. 2, pp. 119–125, 2001.
90. U. Srikantha, J. V. Morab, S. Sastry et al., “Outcome of ven-triculoperitoneal shunt placement in Grade IV tubercular meningitis with hydrocephalus: a retrospective analysis in 95 patients,” Journal of Neurosurgery: Pediatrics, vol. 4, no. 2, pp. 176–183, 2009.
91. R. K. Garg and M. K. Sinha, “Tuberculous meningitis in pa-tients infected with human immunodeficiency virus,” Journal of Neurology, vol. 258, no. 1, pp. 3–13, 2011.
92. V. Asselman, F. Thienemann, D. J. Pepper et al., “Central nervous system disorders after starting antiretroviral therapy in South Africa,” AIDS, vol. 24, no. 18, pp. 2871–2876, 2010.
93. N. Valin, J. Pacanowski, L. Denoeud et al., “Risk factors for ’unmasking immune reconstitution inflammatory syndrome’ presentation of tuberculosis following combination antiretro-viral therapy initiation in HIV-infected patients,” AIDS, vol. 24, no. 10, pp. 1519–1525, 2010.
94. M. E. Tor¨ok,¨ N. T. B. Yen, T. T. H. Chau et al., “Timing of ini-tiation of antiretroviral therapy in human immunodeficiency virus (HIV)-associated tuberculous meningitis,” Clinical Infec-tious Diseases, vol. 52, no. 11, pp. 1374–1383, 2011.
95. S. S. Abdool Karim, K. Naidoo, A. Grobler et al., “Timing of initiation of antiretroviral drugs during tuberculosis therapy,” The New England Journal of Medicine, vol. 362, no. 8, pp. 697–706, 2010.
96. J. E. Kaplan, C. Benson, K. H. Holmes, J. T. Brooks, A. Pau, and H. Masur, “Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adoles-cents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,” Morbidity and Mortality Weekly Report. Recommendations and Reports, vol. 58, no. RR-4, pp.1–207, 2009.
97. M. Caws, G. Thwaites, K. Stepniewska et al., “Beijing genotype of Mycobacterium tuberculosis is significantly associated with human immunodeficiency virus infection and multidrug re-sistance in cases of tuberculous meningitis,” Journal of Clinical Microbiology, vol. 44, no. 11, pp. 3934–3939, 2006.
98. D. Cecchini, J. Ambrosioni, C. Brezzo et al., “Tuberculous meningitis in HIV-infected patients: drug susceptibility and clinical outcome,” AIDS, vol. 21, no. 3, pp. 373–374, 2007.
99. V. B. Patel, N. Padayatchi, A. I. Bhigjee et al., “Multidrug-resis-tant tuberculous meningitis in KwaZulu-Natal, South Africa,” Clinical Infectious Diseases, vol. 38, no. 6, pp. 851–856, 2004.
100. M. E. Torok, T. T. H. Chau, P. P. Mai et al., “Clinical and microbiological features of HIV-associated tuberculous men-ingitis in Vietnamese adults,” PLoS ONE, vol. 3, no. 3, Article ID e1772, 2008.
101. F. A. Khan, J. Minion, M. Pai et al., “Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis,” Clinical Infectious Diseases, vol. 50, no. 9, pp. 1288–1299, 2010.